Are serum type III procollagen and prolyl hydroxylase useful as noninvasive markers of liver disease in patients with cystic fibrosis?

Journal of Pediatric Gastroenterology and Nutrition

Volumn 27, Issue 5, 1998, Pages 603-605

  Leonardi, Salvatore ^a   Giambusso, Francesco ^a   Sciuto, Concetta ^a   Castiglione, Salvatore ^a   Castiglione, Nicolò ^a   La Rosa, Marin ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; PROCOLLAGEN; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE MARKER; ENZYME IMMUNOASSAY; FEMALE; FIBROGENESIS; HUMAN; LIVER BIOPSY; LIVER DISEASE; LIVER FIBROSIS; MALE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RADIOIMMUNOASSAY; STAPHYLOCOCCUS AUREUS;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; INFANT; LIVER DISEASES; MALE; PROCOLLAGEN; PROCOLLAGEN-PROLINE DIOXYGENASE; RADIOIMMUNOASSAY; REGRESSION ANALYSIS;

PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

EID: 0031724915     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005176-199811000-00021     Document Type: Article

References (22)

1. Oppenheimer EH, Easterly JR. Hepatic changes in young infants with cystic fibrosis: Possible relation to focal biliary cirrhosis. J Pediatr 1975;86:688-9.
2. Psacharopoulos HT, Howard ER, Portmann B, Mowat AP, Willi ams R. Hepatic complications of cystic fibrosis. Lancet 1980;II:78-80.
3. Nagel RA, Javaid A, Meire HB, et al. Liver disease and bile duct abnormalities in adults with cystic fibrosis. Lancet 1989: :1422-25.
4. Scott-Jupp R, Lama M, Tanner MS. Prevalence of liver disease in cystic fibrosis. Arch Dis Child 1991;66:698-701.
5. Williams SGJ, Haylle KM, Hodson ME, Westaby D. Prognosis in cystic fibrosis. N Engl J Med 1992;327:1244-5.
6. Williams SG, Westaby D, Tanner MS, Mowat AP. Liver and biliary problems in cystic fibrosis. Br Med Bull 1992;48:877-92.
7. Tanner MS. Liver and biliary problems in cystic fibrosis. J R Soc Med 1992;85(suppl 19):20-4.
8. Weigend K, Zaug P, Frei A, et al. Long term follow-up of serum N-terminal propeptide of collagen type III levels in patients with chronic liver disease. Hepatology 1984;4:835-8.
9. Hoyhtya M, Myllyla R, Piuva J, et al. Monoclonal antibodies to human prolyl 4-hydroxylase. Eur J Biochem 1984;141:477.
10. Trinchet JC, Hartmann DJ, Pateron D, et al. Serum type I collagen and N-terminal peptide of type III procollagen in chronic hepatitis. Relationship to liver histology and conventional liver tests. J Hepatol 1991;12:139-44.
11. Testa R, Bindi P, Risso D, et al. Serum prolyl-hydroxylase as an index of fibrogenetic activity in chronic active hepatitis and cirrhosis. Eur J Gastroenterol Hepatol 1993;5:103-7.
12. Myara I, Cosson C. Hepatic fibrosis: Changes in collagen and serum markers related to its metabolism (in French). Gastroenterol Clin Biol 1988;12:99-106.
13. Weigand K, Zaugg PY, Frei A, et al. Long-term follow up of serum N-terminal propeptide of collagen type III levels in patients with chronic liver disease. Hepatology 1984;4:835-8.
14. Risteli J, Niemi S, Trivedi P, Mowat AP, Risteli L. Rapid equilibrium radioimmunoassay of the amino-terminal propeptide of human type III procollagen. Clin Chem 1988;34:715-8.
15. Johansen HK, Nir M, Hoiby N, Koch C, Schwartz M. Severity of cystic fibrosis in patients homozygous and heterozygous for delta F508 mutation. Lancet 1991;337:631-4.
16. De Arce M, O'Brien S, Hegarty J, et al. Deletion delta F508 and clinical expression of cystic fibrosis-related liver disease. Clin Genet 1992;42:271-2.
17. Colombo C, Apostolo MG, Ferrari M, et al. Analysis of risk factor for the development of liver disease associated with cystic fibrosis. J Pediatr 1994;124:393-9.
18. Maurage C, Lenaerts C, Weber AM, Brochu P, Yousef I, Roy CC. Meconium ileus and its equivalent as a risk factor for the development of cirrhosis: An autopsy study in cystic fibrosis. J Pediatr Gastroenterol Nutr 1989;17-20.
19. Lindblad A, Hultcrantz R, Strandvik B. Bile-duct destruction and collagen deposition: A prominent ultrastructural feature of the liver in cystic fibrosis. Hepatology 1992;16:372-81.
20. Colombo C, Crosignani A, Assaisso M, et al. Ursodeoxycholic acid therapy in cystic fibrosis-associated liver disease: A dose response study. Hepatology 1992;16:924-30.
21. Colombo C, Bertolini E, Assaisso ML, Bettinardi N, Giunta A, Podda M. Failure of ursodeoxycholic acid to dissolve radiolucent gallstones in patients with cystic fibrosis. Acta Paediatr 1993;82: 562-5.
22. Gerling B, Becker M, Staab D, Schuppan D. Prediction of liver fibrosis according to serum Collagen VI level in children with cystic fibrosis. N Engl J Med 1997;336:1611-2.